PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
December 15, 2017Journal of GastroenterologyOpen Access

Current and future pharmacological therapies for NAFLD/NASH

View Full Paper
Ask AI
Bookmark
Share

Population

Patients with nonalcoholic fatty liver disease (NAFLD) or nonalcoholic steatohepatitis (NASH)

Design

Review

Key result

Vitamin E and pioglitazone are currently recommended for NASH, while novel agents targeting hepatic fat, oxidative stress, gut microbiome, and fibrosis are in phase 3 trials.

Authors

YSYoshio SumidaMYMasashi Yoneda

Discussion

Loading...

Member takes

Overview

GLP-1RAs and SGLT2i may benefit NASH with cardiometabolic comorbidities; extends diabetes data to liver outcomes in late-phase trials.

Structured PICO

P
Population
Patients with nonalcoholic fatty liver disease (NAFLD) or nonalcoholic steatohepatitis (NASH)
I
Intervention
Pharmacological therapies including vitamin E, pioglitazone, GLP-1RA, SGLT2 inhibitors, and emerging agents targeting hepatic fat, oxidative stress, microbiomes, and fibrosis

This review highlights the pipeline of pharmacological therapies for NASH, categorizing them by their targets: hepatic fat accumulation, oxidative stress/inflammation, intestinal microbiomes, and hepatic fibrosis.

Limitations

  • No approved pharmacotherapy currently exists for NAFLD/NASH
  • Long-term efficacy and safety of current off-label treatments like vitamin E and pioglitazone remain to be fully established

Cite This Study

Sumida et al. (2017) conducted a review in Nonalcoholic fatty liver disease (NAFLD) and Nonalcoholic steatohepatitis (NASH). Pharmacological therapies was evaluated. Vitamin E and pioglitazone are currently recommended for NASH, while novel agents targeting hepatic fat, oxidative stress, gut microbiome, and fibrosis are in phase 3 trials.

synapsesocial.com/papers/6a63c47a2cb75007f4926d96https://doi.org/10.1007/s00535-017-1415-1
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Advances in pharmacotherapy of NASH2025
  2. 2NASH Therapy: omega 3 supplementation, vitamin E, insulin sensitizers and statin drugs2017 · 54 citations
  3. 3Advancements in Non-Alcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis Treatment: From Lifestyle Interventions to Novel Therapies2024
  4. 4Nonalcoholic steatohepatitis2011 · 125 citations
  5. 5Non-alcoholic fatty liver disease: What has changed in the treatment since the beginning?2014 · 51 citations